(888) 391-1315



The maker of Pradaxa has settled more than 4,000 cases linking the drug to internal bleeding.

SEE THE SIDE EFFECTSthe pradaxa litigation

Did you suffer internal bleeding after taking Pradaxa?

pradaxa bleeding

ABOUT pradaxa

Pradaxa is the brand name for dabigatran, a blood thinner prescribed to patients with atrial fibrillation. The drug is designed to prevent blood clots, stroke, and pulmonary embolism. Pradaxa was approved by the FDA in 2010, and is sold by the German drug company Boehringer Ingelheim.

Pradaxa has been linked with serious health risks, such as irreversible internal bleeding, heart attack, brain hemorrhaging and even death.

In 2014, Boehringer Ingelheim, the maker of Pradaxa, paid approximately $650 million to settle around 4,000 lawsuits alleging the drug caused internal bleeding, brain hemorrhaging or death.

Unfortunately, this settlement only covered cases filed prior to May of 2014. Now, lawyers are filing new Pradaxa lawsuits in 2015 to help those victims that did not receive compensation from the first litigation, or those injured since May 2014.

In short:

  • pradaxa brain hemorrhage

    Pradaxa is still on the market and has not been recalled.

  • internal bleeding pradaxa

    Internal bleeding and brain hemorrhaging risks have been identified.

  • internal bleeding side effects pradaxa

    Attorneys have settled cases for around 4,000 people.

pradaxa internal bleeding

side effects

Pradaxa patients that have suffered from internal bleeding or brain hemorrhaging while using the drug may be eligible for compensation. 

The most common Pradaxa side effects are gastrointestinal internal bleeding. 

pradaxa settlement

legal assistance

The maker of Pradaxa has already settled more than 4,000 cases for $650 million.

Lawyers are continuing to file new lawsuits for those not included in the first settlement or who have suffered recent bleeding injuries.

pradaxa news

latest news

Although the Pradaxa federal MDL litigation has been closed, lawyers are now pursuing cases on behalf of those injured in a special state court. If you have additional questions, please feel free to contact a patient advocate.

Assistance is available. Speak with a patient advocate today.


The maker of Pradaxa has settled approximately 4,000 lawsuits for serious internal bleeding, but has not yet agreed to compensate new victims. Lawyers are now offering legal assistance to those injured by Pradaxa bleeding and filing cases in a new court.

pradaxa RECALL

Pradaxa has been prescribed to millions of patients in more than 70 countries. Soon after FDA approval, however, reports of serious health risks emerged, including uncontrolled internal bleeding.

Pradaxa has been linked to these serious conditions: 

  • Bleeding in the brain (brain hemorrhage)
  • Bleeding in the intestines
  • Bleeding in the kidneys
  • Heart attack

At this time, there is no official Pradaxa recall. However, a federal judge recently ruled that those affected by Pradaxa side effects, or family members who have lost a loved one, can proceed with lawsuits.

pradaxa statistics



The popular blood thinning drug Pradaxa has been prescribed to millions of patients with atrial fibrillation to prevent blood clots, stroke, and pulmonary embolism. However, this medication has been linked to dangerous health risks.

Common side effects from using Pradaxa:

Researchers have also linked Pradaxa with these serious conditions:

The drug was approved by the FDA in 2010. According to the FDA database, by 2012, over 17,000 people reported adverse side effects from using Pradaxa. In addition, 6,249 hospitalizations and 1,847 patient deaths were determined to be caused by Pradaxa use.

severe internal bleeding pradaxa

severe Internal bleeding

Problems with Pradaxa were reported immediately after the drug’s release to market. Within six months, the FDA received over 500 reports of  internal bleeding or death among patients. Such reports are a rarity with the older drugs, Coumadin and Warfarin. There are no reversal agents for Pradaxa.

pradaxa brain hemorrhage

brain hemorrhaging

Soon after FDA approval, reports began to show that Pradaxa could cause serious and potentially irreversible internal bleeding. Within the first six months after the drug's release, the FDA received more than 500 reports of internal bleeding and deaths from conditions like brain hemorrhages. 

death from pradaxa

Rate of death

The maker of Pradaxa faces liability because it did not warn patients that there is no reversal agent to stop internal bleeding, a severe side effect of the drug. 

The rate of deaths among Pradaxa users was so high in 2011 that the FDA launched an investigation into the drug’s safety. That year, the agency received reports of 542 deaths among users, which led the death rate among all other drugs. 

pradaxa anticoagulant

anticoagulant dangers

In January of 2013, the Institute for Safe Medication Practices again ranked anticoagulants like Pradaxa among the most dangerous of all outpatient drugs. In addition, it reviewed thousands of adverse event reports submitted to the FDA. SMP concluded that internal bleeding caused by Pradaxa is nearly five times more likely to result in death than with Warfarin. 

pradaxa medical risks

Manufacturer: Boehringer Ingelheim

Pradaxa's manufacturer, Boehringer Ingelheim, faces liability for losses and damages to its consumers because it did not warn patients of these risks. Furthermore, the drug maker has a history of negligence.

Boehringer Ingelheim produces a large number of medications to treat abdominal pain, bladder disorders, COPD (chronic obstructive pulmonary disease), respiratory disease, acid reflux, ulcers, cardiovascular disease, Parkinson's disease, HIV, and thromboembolic disease. The company’s more widely known products include Pradaxa, Zantac, Spiriva, Flomax, Dulcolax, and Metacam.

The FDA has issued multiple serious safety violations against this company.

In 2011, the FDA shut down a drug manufacturing plant that was a Boehringer Ingelheim subsidiary. Inspectors noted that the Ohio facility contained mold, rusty tools, and a barrel of urine. The company then spent $300 million to appropriately upgrade the plant.

Most recently, Boehringer’s blockbuster drug Pradaxa has been the center of controversy. Pradaxa is linked to thousands of injuries and hundreds of deaths from uncontrollable internal bleeding.

Within weeks of the FDA’s approval of Pradaxa, further research by MedWatch showed the agency had received more reports of side effects from Pradaxa than 98 percent of any of the other drugs on the market. Complaints included internal bleeding in the brain, intestines, and kidneys, as well as heart attacks.

On December 7, 2011, the FDA launched an investigation into Pradaxa following reports of 3,781 side effects and 542 deaths, the highest number of cases reported for any drug that year.

pradaxa side effects
safety warnings pradaxa

Pradaxa Safety Warnings

Experts still disagree about whether Pradaxa has higher risks for internal bleeding. The FDA has advised that the drug is as safe as the more common prescribed the blood thinner Warfarin.

However, the Institute for Safe Medication Practices has named Pradaxa one of the most dangerous drugs on the market and warned that patients suffering from internal bleeding after taking Pradaxa are nearly five times more likely to die from this condition than those with internal bleeding after taking Coumadin or Warfarin.

Research and Studies

Additionally, a study from the University of Illinois at Chicago has suggested that the FDA's data may be flawed, and the risk for bleeding may be higher than the agency thought. Most recently, researchers in Denmark discovered that patients may be using Pradaxa improperly, and there may be higher risks of internal bleeding when switching from other blood thinners.

While all blood thinners can cause internal bleeding, most, like Coumadin or Warfarin, have "reversal agents" that can be used in the case of emergency. Doctors have reported that once Pradaxa causes bleeding, there is little they can do to stop it.

pradaxa studies
view sources

Holster, L. New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. Gastroenterology. (March 7, 2013). Retrieved from www.gastrojournal.org

QuarterWatch. Update on Anticoagulants dabigatran (PRADAXA) and rivaroxaban (XARELTO). Institute for Safe Medication Practices. (January 9, 2013). Retrieved from www.ismp.org